Background/Aims: MicroRNAs (miRNAs) or exosomes have recently been shown to play vital regulatory or communication roles in cancer biology. However, the roles and mechanisms of exosomal miRNAs in pancreatic ductal adenocarcinoma (PDAC) remain unknown. We aimed to investigate the detailed roles and mechanisms of tumor-generated exosomal miRNAs in progression of PDAC. Methods: miR-222 was identified by miRNA microarray studies in exosomes of PDAC cells, and further analyzed in plasma exosomes of PDAC patients. The regulatory mechanisms of miR-222 were explored by qRT-PCR, WB, dual-luciferase assays and immunofluorescence or confocal analysis. Other biological assays include transwell, xenograft models and so on. Results: miR-222 is significantly high in tumor exosomes or highly invasive PDAC cells. miR-222 could directly regulate p27 to promote cell invasion and proliferation. miR-222 could also activate AKT by inhibiting PPP2R2A expression, thus inducing p27 phosphorylation and cytoplasmic p27 expression to promote cell survival, invasion and metastasis. Expressions of miR-222 and p27 were significantly inversely correlated, and cytoplasmic p27, instead of nuclear p27, was associated with tumor malignancy. miR-222 could be transmitted between PDAC cells via exosome communication, and the exosomal
Introduction
With a 5-year survival rate of approximately 5%, pancreatic ductal adenocarcinoma (PDAC) is the deadliest of all solid malignancies [1, 2] . Surgical resection remains the only potentially curative therapy, but most PDAC patients are diagnosed at advanced stages and miss their chance for operation [3, 4] . This disappointing outcome is partly due to the uncontrolled rapid tumor growth and invasion of PDAC. Many studies have revealed that tumor growth and invasion are complicated processes that involve many oncogenes or pathways [5] . p27 Kip1(p27), also called cyclin-dependent kinase inhibitor B, is one of the most important oncogenes related to tumor cell cycle regulation and tumor invasion [6, 7] ; the PI3K/AKT signaling pathway also participates in many physiological processes, including cell proliferation and apoptosis inhibition [8, 9] . Detecting the pathological and molecular mechanisms of PDAC may facilitate the discovery of new therapeutic targets or diagnostic biomarkers in clinical practice.
MicroRNAs (miRNAs) are a class of small noncoding RNAs that negatively regulate gene expression at the post-translational level [10] . By binding to the 3'UTR of the target gene, miRNAs mediate translational repression primarily via mRNA degradation [11, 12] . To date, a large number of tumor-related miRNAs have been identified to play key roles in many biological processes, including cell proliferation, invasion, and metabolism [13] [14] [15] . However, the majority of identified miRNAs are tumor suppressor genes; although several studies have reported serum miRNA correlations with different tumors, such studies of PDAC are rare, and the origins of the serum miRNAs remain unidentified [16] . Thus, the investigation of serum tumor-promoting miRNAs in PDAC is urgently needed.
Exosomes are small membrane vesicles (diameters ranging from 40-100 nm) that are saucer-like flattened spheres released from different cells [17] . Exosomes were first identified in mammalian reticulocytes, but their presence has been confirmed in different tumor cells; they can transfer a wide variety of biological components, including proteins, miRNAs, mRNAs, lncRNA and circular RNAs, to other recipient cells via cellular communication [18, 19] . Recently, more and more studies have shown that tumor exosomes play key roles in cell communication, the immune system and tumor invasion. Thus, biomarkers in exosomes may be suitable for diagnostic use in clinical practice [20, 21] . So far, several studies have shown that tumor-related miRNAs exist in exosomes and play important roles in angiogenesis, tumor invasion and metastasis [22] [23] [24] . However, the origin of miRNAs in exosomes remains unclear, and studies of tumor-related miRNAs in exosomes in PDAC are unknown.
In this study, we identified a tumor-promoting miRNA (miR-222) in tumor exosomes by microarray analysis; its functions and detailed molecular mechanisms were also determined. We further confirmed the transfer of miR-222 between tumor cells by exosomes, and the expression of miR-222 in plasma exosomes was also analyzed in clinical PDAC samples. Ultimately, we further proved the tumor released miR-222 in blood exosomes in vivo conditions and put forward a hypothesis about how tumor released miR-222 functions in pancreatic cancer.
cultured with conditioned medium with 10% d-FBS, and 10 ml culture medium was used for exosomes extraction by Total Exosome Isolation Kit (Thermo, USA). To label exosomes, 2.5ug/ml Dil was added before the mixture were centrifuged for 1 h. Plasma exosomes extraction was carried out as previous discussed, briefly, 2 ml of fresh plasma was collected from each patient and the exosomes were extracted using ExoQuick TM Exosome Precipitation Solution (SBI, USA). For exosomes quantification, the FLUOROCET Ultrasensitive Exosome Quantitation Assay Kit (SBI, USA) was used to ensure the same number of exosomes was used in each experiment. As discussed before, 5×10 8 exosomes were used for exosomal RNA extraction, 1×10 8 exosomes were used for exosomes-stimulation experiment in vitro. The size and morphology were further confirmed by transmission electron microscopy (TEM).
Microarray analysis
Exosomes of Hs 766T and Hs 766T-L2 cells were purified and total RNAs were extracted using TRIzol LS (Thermo, USA) according to the manufacturer's instructions, then RNAs were treated with RNase R to remove other non-circular RNAs. RNA expression profiling was performed using Arraystar Human miRCURYTM LNA Array (Arraystar, USA). Briefly, After quality control, the miRCURY™ Hy3™/Hy5™ Power labeling kit (Exiqon, Vedbaek, Denmark) was used according to the manufacturer's guideline for miRNA labelling. After stopping the labeling procedure, the Hy3™-labeled samples were hybridized on the miRCURYTM LNA Array (v.18.0) (Exiqon) according to array manual. Then the slides were scanned using the Axon GenePix 4000B microarray scanner (Axon Instruments, Foster City, CA).
Cell migration and invasion assay
Cell migration was examined by a wound-healing assay according to previously described. Briefly, PDAC cells were cultured regularly until reaching confluence and the medium was replaced with serum-free 1640 medium, wounds were made with a 10 μl-pipette tip and photos were captured by phase-contrast microscope. Cell invasion ability was evaluated by a transwell assay as described previously. Briefly, 5×10
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PDAC cells in 300 μl of serum-free medium were cultured in a chamber containing an 8 μm polycarbonate filter (Millipore, USA) coated with 30 μl of Matrigel (BD, USA), After incubating for 36 h, cells remaining on the upper membrane were removed with a cotton swab and cells that had penetrated the membrane were fixed with 4% formaldehyde and then stained with 0.5% crystal violet for 20 min. All the statistical results were obtained from three independent experiments averaged from five randomly selected image fields.
Immunofluorescence
Immunofluorescence assays were taken as previously described. Briefly, PDAC cells were seeded and cultured on cell slides and then transfected with miRNA or incubated with exosomes, then cells were fixed, permeabilized, blocked by incubating with 1% bovine serum albumin (Sigma, USA). The cells were then incubated with primary antibodies specific for anti-p27 (1:800, #3686, CST, USA) overnight at 4℃. The cells were then incubated with a goat anti-rabbit IgG (fluorescein labeled, 1:500, PIERCE, USA) secondary antibody for 1 h at 37℃. The slides were mounted with Mounting Medium for Fluorescence with DAPI (Vector Laboratories, USA) and imaged with a fluorescence microscope.
5-Ethynyl-2'-deoxyuridine (EdU) incorporation assay
The EdU assay was performed with a keyFluor488 Click-iT EdU detection kit (KGA331-100, KeyGene, Nanjing, China) according to the manufacturer's instructions as previously described. Briefly, PADC cells were seeded on cell slides in a 6-well plate, after the treatment of circ-RNA transfection or exosomes addition, cells were incubated with 50 Μm EdU for 2 h, then cells were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 for 15 min, then cells were incubated with Click-It reaction mixture for 30 min, the slides were mounted with Mounting Medium for Fluorescence with DAPI (Vector Laboratories, USA) and imaged with a fluorescence microscope.
RNA isolation and qRT-PCR analysis
Cellular RNA was isolated using TRIzol reagent (Thermo, USA) and exosomal RNA was extracted by TRIzol LS (Thermo, USA). First-strand cDNA was generated with PrimeScript RT Reagent Kit with gDNA Eraser (TaKaRa, Japan) and miRNA reverse transcription was performed using a Mir-X miRNA qRT-PCR SYBR Kit (Clontech, Japan). Real-time PCR was performed using the PrimeScript RT Reagent Kit and SYBR Premix Ex Taq (TaKaRa, Japan) on a CFX96 Real-Time System (Bio-Rad, USA) with the reaction conditions provided in the instructions. The primer details used in the study were miR-222 (F: AGCTACATCTGGCTACTGGGT); U6 (F: CTCGCTTCGGCAGCACA, R: AACGCTTCACGAATTTGCGT); p27 (F: TCGGGGTCTGTGTCTTTTGG, R: AGACACTCGCACGTTTGACA); beta-actin (F: GCGGACTATGACTTAGTTGCGTTACA, R: TGCTGTCACCTTCACCGTTCCA). Additionally, the miRNA mRQ 3' primer was provided in the Mir-X miRNA qRT-PCR SYBR Kit (Clontech, Japan).
Western blot analysis
Total protein of PDAC cells was extracted by RIPA lysis buffer (Thermo, USA) containing protease inhibitor cocktail tablets (Roche, USA) and exosomal protein was isolated using Exosome RNA and Protein Isolation Kit (Thermo, USA). After measured by BCA Protein Assay Kit (Beyotime, China), equal amounts of protein (30 μg) were used to SDS-page on 10% polyacrylamide gels and transferred to PVDF membranes (Millipore, USA), which were blocked and blotted with primary antibodies overnight at 4℃. The antibodies used in this study included the following: anti-p27 (1:800, #3686, CST, USA), anti-p-p27 (1:1000, ab85047, abcam, USA), anti-PPP2R2A (1:1000, #5689, CST, USA), anti-Histone H1(1:1000, 15446-1-AP, Proteintech, USA), anti-β-actin (1:5000, 20536-1-AP, Proteintech, USA), anti-AKT (1:1000, 4691, Cell Signaling, USA), antip-AKT (1:1000, 4060, Cell Signaling, USA) and anti-CD63 (1:500, 10628D, Thermo, USA). The membranes were washed with PBST and incubated with horseradish peroxidase-conjugated secondary antibody for 2 h and the immunocomplexes were then visualized using a New Super ECL Detection Kit (KeyGEN BioTECH, China) according to the manufacturer's protocol. of 43 fresh frozen tissues were used for RNA isolation, fresh tissues were put into liquid-nitrogen immediately after tumor excision and then transferred to -80℃ for future use. For plasma exosomes isolation, 10 ml of total blood of each patient was collected and plasma was isolated by a centrifuge 3000 rpm for 20 min. the plasma supernatant was stored at -80℃ for future use. Especially, each extracted RNA sample was subjected to an agarose electrophoresis. All patients were followed up by radiography, ultrasonography or CT examination every 3 months after discharge and were followed up monthly by telephone in the clinical follow up center of the Department of Hepatobiliary Surgery Institute, Southwest Hospital. This study was approved by the Ethics Committee of Southwest Hospital, and all patients provided written informed consent.
PDAC patients and clinical samples

Animal experiment
All animal experiments were approved by the Institutional Animal Care and Use Committee of Southwest Hospital, Chongqing, China. Briefly, Four-to six-week-old male randomly selected athymic nude mice were obtained from Southwest Hospital (Chongqing, China) and housed in the standard pathogen-free conditions of Southwest Hospital (Chongqing, China). The mice were anesthetized by an intraperitoneal injection of 1% pentobarbital sodium (50 mg/kg). A median abdominal incision was made to expose the spleen and pancreas, and 5 × 10 6 PDAC cells (in 100 µl of PBS) were injected to the head of the pancreas. After replacing the pancreas and closing the abdomen, the mice were imaged by the IVIS Lumina II system (Caliper Life Science, USA). All mice were sacrificed at 4 weeks after the procedure, and the pancreas were fixed in 4% paraformaldehyde and subjected to hematoxylin-eosin (H&E) staining.
Dual-luciferase reporter assay 5×10
3 cells were cultured in a white 96-well plate and then transfected with psiCHECK2-circ-PDE8A or psiCHECK2-circ-PDE8A mut plasmid (Sangon Biotech, China) and 8 ng of the internal control pRL-TK Renilla luciferase plasmid (Promega, USA), together with miR-338 (RiboBio, China) or miR-23a (RiboBio, China) at a final concentration of 0, 50 or 150 nM. After a 48-h incubation, the cells were harvested and processed with the Dual-Luciferase Reporter Assay System (E1910, Promega, USA) according to the manufacturer's protocol. The results were quantified as the ratio of firefly luciferase activity/Renilla luciferase activity in each well.
Statistical analysis
The correlation between clinical categorical parameters and plasma exosomal miR-222 expression (the median was regard as cutoff value) was evaluated by a χ 2 test. Student's t-test was used to compare group differences if they followed a normal distribution; otherwise, the nonparametric Mann-Whitney test was adopted. One-way ANOVA was applied to compare the differences among 3 groups. For survival analysis, univariate analysis was conducted by the KM method (the log-rank test), and multivariate analysis was performed by the stepwise Cox multivariate proportional hazard regression model (Forward LR, likelihood ratio). All analyses were performed using SPSS 22.0 software (IBM, USA), all the tests are two-sided and a P-value <0.05 was considered to be statistically significant. All statistical analyses were completed under the guidance of experienced experts from the Statistics Department of the Army Medical University. 
Results
The identification of miR-222 in PDAC exosomes
Our previous studies have shown that exosomes from Hs 766T-L2 cells are much more invasive than those from Hs 766T cells. To investigate the possible tumor-related miRNAs in exosomes, we profiled the miRNA expression in exosomes from Hs 766T and Hs 766T-L2 cells. The entire screening procedure is shown in Fig. 1A . Of the dozens of differentially expressed miRNAs, we noted that miR-222 was the most differentially expressed miRNA in tumor exosomes, with a fold-change of 177.72 (Fig. 1B) . We next confirmed the high expression levels of miR-222 in exosomes from Hs 766T-L2 cells by qRT-PCR (Fig. 1C ). Furthermore, we tested the miR-222 expression in 6 PDAC cell lines and in the normal pancreatic cell lines HPDE and HEK 293. We found that the expression levels of miR-222 were much higher in PDAC cells than those in HPDE or HEK 293 cells (Fig. 1D) . To confirm these results, we chose to investigate Hs 766T (the parent cell), Hs 766T-L1, Hs 766T-L2 and Hs 766T-L3 (the daughter cell) cells (Hs 766T-L1, Hs 766T-L2 and Hs 766T-L3 cells are the first, second and third-generation primary tumor cells with increasing invasive ability and derived from a liver metastasis of Hs 766T cells, respectively) [25] [26] [27] ; as the malignancy of PDAC cells increased, the expression levels of miR-222 also increased successively (Fig. 1E) . Thus, we speculate that miR-222 may have an important function in PDAC. We found that the expression levels of miR-222 were the highest in Hs 766T-L3 cells and the lowest in Capan-1 cells (Fig. 1D and 1E); so we further confirmed its upregulation (miR-222 lentivirus) or downregulation (miR-222 shRNA) in Hs 766T-L3, Capan-1 and HEK 293 cells (Fig. 1F) . Together, we screened miR-222 in the tumor exosomes and further confirmed that miR-222 was highly expressed in malignant PDAC cells.
miR-222 promotes cell invasion and proliferation in PDAC cells
As miR-222 was highly expressed in malignant cells, we wondered whether miR-222 could promote cell migration or invasion. As expected, wound-healing assays indicated that miR-222 increased the migration of Capan-1 cells, while miR-222 shRNA (si miR-222) decreased the migration of Hs 766T-L3 cells ( Fig. 2A-B) . Transwell assays also proved that miR-222 promoted cell invasion in Capan-1 and Hs 766T-L3 cells (Fig. 2C-D) . To further investigate the role of miR-222 in cell motility, Phalloidin-stained actin filaments were examined in NC or miR-222-overexpressing (ov miR-222) PDAC cells. We found that miR-222 increased the number of filopodia in Capan-1 cells (Fig. 2E and Fig. S1A -B -for all supplemental material see www.karger.com/10.1159/000495281) and the number of lamellipodia in Hs 766T-L3 cells (Fig. 2F and Fig. S1C-D) . Furthermore, EdU assays proved that miR-222 overexpression increased cell proliferation in Capan-1 cells (Fig. 2G and Fig.  S2A-C) , while the miR-222 inhibitor decreased cell proliferation in Hs 766T-L3 cells (Fig. 2H and Fig. S2D-F) . We further study the effect of miR-222 on cell cycle; the results indicated that miR-222 overexpression increased the number of cells in G2 or S phase and decreased the number of cells in G1 phase (Fig. 2I) . Together, the above results showed that miR-222 could promote cell migration, invasion and proliferation in PDAC cells.
miR-222 regulates the expression and localization of p27
To determine the detailed molecular mechanism of miR-222, we used bioinformatics tools (Miranda and Target Scan) to analyze the possible molecular target. As shown in Fig. 3A , we noted that p27, a classic oncogene, has two 8-mer binding sites for miR-222, and previous studies have reported that p27 can be regulated by miR-222 in Hela cell [28] . Therefore, we further verified the regulation of miR-222 to p27 in PDAC cells. The qRT-PCR results showed that p27 was inhibited by miR-222 overexpression in Capan-1 cells and was overexpressed in Hs 766T-L3 cells treated with a miR-222 shRNA (Fig. 3B) . The WB assays also showed similar results (Fig. 3C-D) . To confirm this regulation, we constructed wild type or mutated p27 3'UTR firefly luciferase plasmids, in which the two miR-222 binding sites are deleted, the details of these plasmids are shown in Fig. 3E and Table S1 . The dual-luciferase reporter
Next, we confirmed the regulation of miR-222 by p27 in PDAC cells by immunofluorescence assays. First, we confirmed that the expression levels of p27 were obviously higher in Capan-1 cells (Fig. 3G ) than in Hs 766T-L3 cells (Fig. 3H) , and the results showed that the high expression levels of p27 were inhibited by miR-222 overexpression in Capan-1 cells (Fig. 3I-J) . Interestingly, we found that p27 was located primarily in the nucleus in Capan-1 (Fig. 3G ) but in the cytoplasm in Hs 766T-L3 cells (Fig. 3H) ; when Capan-1 cells were treated with miR-222, nuclear p27 obviously decreased while cytoplasmic p27 evidently increased (Fig. 3I-J and Fig. S3 ). Therefore, we measured p27 phosphorylation in miR-222-overexpressing PDAC cells; the WB results showed that miR-222 not only decreased p27 expression levels but also induced p27 phosphorylation in PDAC cells (Fig. 3C-D , the second column). Together, we found that miR-222 could decrease p27 expression levels and increase p27 phosphorylation, which may induce the increasing cytoplasmic p27 expression.
miR-222 promotes p27 phosphorylation via activating AKT
Next, we investigated how miR-222 promoted AKT phosphorylation. As several studies reported that miR-222 could activate AKT through inhibiting PPP2R2A [29] , we verified the result in PDAC. As expected, WB results showed that miR-222 inhibited the expression of PPP2R2A in Capan-1 and Hs 766T-L3 cells (Fig. 4A-B) . Further studies confirmed that miR- 222 activated AKT by promoting its phosphorylation, to confirm the AKT phosphorylation (i.e. AKT activation) results, we treated cells with LY294002, an AKT inhibitor, and found that miR-222-induced AKT phosphorylation was inhibited by LY294002 (Fig. 4C-D) .
The results above showed that miR-222 could activate AKT and promote p27 phosphorylation; thus, we wondered whether miR-222 promoted p27 phosphorylation via activating AKT. An AKT activator (IGF-1) and inhibitor (LY294002) were used in this study. We found that LY294002 did not affect the p27 phosphorylation in untreated PDAC cells (data not shown); further research showed that AKT could be activated by IGF-1 and miR-222, but AKT phosphorylation levels were higher in the IGF-1 group than in the miR-222 group. In addition, the AKT activation induced by miR-222 was further blocked by the addition of LY294002. These results were confirmed in both Capan-1 and Hs 766T-L3 cells (Fig. 4E-F) .
Previous studies revealed that p27 could be phosphorylated by AKT at T-157, which further affect the expression localization of p27 [30, 31] . Next, we studied the relationship between AKT and p27 phosphorylation and the localization of p27. Capan-1 cells were treated with IGF-1, miR-222 or LY294002, and the nuclear and cytoplasmic proteins of each group were separated by special kits; the WB results showed that the majority of p27 was indeed expressed in the nucleus in the NC group. Once the cells were treated with IGF-1 or miR-222, p27 was highly expressed in the cytoplasm instead of in the nucleus. However, when Capan-1 cells were treated with miR-222 and LY294002, the expression of p27 in the cytoplasm was decreased (Fig. 4G) .
Furthermore, because miR-222 is related to tumor progression and miR-222-overexpressing Capan-1 cells expressed more cytoplasmic p27 than the untreated cells, we suggest that in contrast to nuclear p27, cytoplasmic p27 is associated with tumor malignancy. The immunofluorescence results showed that the cytoplasm levels of p27 in cells, ranked from low to high, are HPDE, Hs 766T and Hs 766T-L3 cells; the nuclear p27 levels were opposite (Fig. 4H-K) . Together, our results showed that miR-222 promotes p27 phosphorylation via activating AKT, which increases the cytoplasmic p27 expression and tumor progression.
miR-222 promotes tumor progression in vivo
Our results above showed that miR-222 expression in PDAC cells, ranked from high to low, was Hs 766T-L3, Hs 766T-L2, Hs 766T-L1, Hs 766T and HPDE cells. We next measured their p27 expression. Interestingly, their p27 expression levels were the opposite of their miR-222 expression levels (Fig. 5A) . To confirm this result in vivo, we analyzed the expression levels of miR-222 and p27 in 43 clinical pancreatic tumor samples. Similarly, we found that the expression levels of miR-222 and p27 were significantly inversely correlated (r=-4.14, p=0.006) (Fig. 5B) .
We next studied the role of miR-222 in in vivo conditions. Capan-1 NC cells (NC) or stable miR-222-overexpressing Capan-1 cells (ov miR-222) were injected into the head of the pancreas of nude mice. The pancreatic tumor of each mouse was analyzed every week by a luciferase IVIS system (Fig. 5C ). The in vivo imaging results showed that the luciferase intensity of the ov miR-222 group was significantly higher than that of the NC group ( Fig.  5D and E) . A month later, the pathological examination results showed that the pancreatic tumors of the ov miR-222 group were obviously larger than those of the NC group (Fig. 5F-H) .
Imaging exosome communication in PDAC cells
As we screened miR-222 in tumor exosomes, we next studied the exosome communication in PDAC cells. First, exosomes of Hs 766T-L3 were confirmed by TEM analysis (Fig. 6A) . Calcein-AM-labeled Capan-1 cells were cocultured with Dil-labeled exosomes (purified from the conditioned medium of Hs 766T-L3 cells) for 24 h, and the live cells were observed with a fluorescence microscope; the results showed dotted, red exosome signals in the cytoplasm of Capan-1 cells (Fig. 6B and Fig. S4A ). To further confirm these results, we labeled exosomes 
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Furthermore, RFP-labeled Capan-1 and exo-Hs 766T-L3 cells were mixed together at a 1:1 ratio for a 48-h co-cultivation; the fluorescence results also showed green, dotted exosomal signals in the cytoplasm of the red Capan-1 cells (Fig. 6E and Fig. S4C ). To confirm the transmission of miR-222 between PDAC cells via exosomes, Hs 766T-L3 cells were transfected with cy5-miR-222. Two days later, the cells were washed with PBS, and the cell exosomes (labeled with Dio dye) were purified from the medium a day later; then, the exosomes were added to Capan-1 cells for a 24-h co-cultivation. The fluorescence results showed red miR-222 signals and green, dotted exosomal signals (Fig. 6F and Fig. S4D) . Together, these data confirm the transmission of miR-222 between PDAC cells via exosomes.
Exosomal miR-222 is an independent risk factor for PDAC patient survival
We confirmed exosomal miR-222 transmission between PDAC cells; next, we wondered whether the miR-222 transmission was functional. Thus, exosomes from miR-222-overexpressing Hs 766T-L3 cells were purified and added to Capan-1 cells (+exosome group) for qRT-PCR and WB analysis. The results showed that compared with the addition of PBS (NC group), the addition of miR-222 exosomes increased the miR-222 expression (Fig.  7A) , and induced the phosphorylation of AKT and p27 and decreased p27 expression levels (Fig. 7B) . Transwell ( Fig. 7C-D) and EdU ( Fig. 7E-F ) assays also showed that the addition of miR-222 exosomes promoted the proliferation of Capan-1 cells. To further study the tumor released exosomes in vivo conditions, Capan-1 cells were transfected by miR-222 and GFP-CD63 lentiviruses together and injected to pancreas to form pancreatic cancer in mice. A month later, we did the peripheral blood (from tail vein) smear test, and under the confocal microscopy analysis we identified the green GFP signals, which were mainly located in red cells (Fig. 7G) , the results suggest that tumor secreted exosomes could enter into blood circulation system. Furthermore, we found that the expression level of miR-222 was elevated compared to NC group mice (Fig. 7H) .
These results above suggest that exosomal miR-222 may play important roles in PDAC; next, we collected plasma from 73 clinical PDAC patients. The exosomes were purified, and confirmed by TEM (Fig. 7I) , and exosomal RNA was extracted from these samples for miR-222 analysis. We found that exosomal miR-222 was significantly associated with tumor size, tumor differentiation and TNM stage (Table 1) . A survival analysis revealed that exosomal miR-222 was related to low survival rates in PDAC patients (Fig. 7J) , and multivariate analyses showed that both exosomal miR-222 and TNM stage were independent risk factors for PDAC survival (Table 2) . Based on our above results, we summarized the role of miR-222 in PDAC (Fig. 7K) . miR-222 has two roles in PDAC: on the one hand, miR-222 decreases p27 expression to induce cell invasion and proliferation; on the other hand, miR-222 inhibits PPP2R2A and activates AKT, which led to p27 phosphorylation and cytoplasmic p27 expression. These effects induced cell survival, invasion and metastasis. In addition, miR-222 can be transmitted via exosomes, and this transmission is functional.
Discussion
In this study, we identified miR-222 using a microarray analysis of exosomes from highly metastatic PDAC cells. Further research revealed that miR-222 could directly regulate p27 to promote cell proliferation and invasion and could also activate AKT by inhibiting PPP2R2A expression, thus inducing p27 phosphorylation and cytoplasmic p27 expression to promote cell survival, invasion and metastasis. Interestingly, these processes could be mediated by exosome transmission. We also measured plasma exosomal miR-222 in 73 PDAC patients and found that exosomal miR-222 is associated with tumor progression and is an independent risk factor for PDAC survival.
Recently, many studies of tumor-related miRNAs in different types of tumors have emerged; different miRNAs have been reported to modulate almost all physiological processes of tumor initiation, invasion, and metastasis [32, 33] . In PDAC, similar to other tumors, the majority of tumor-related miRNAs are tumor suppressors; for example, the miR-200 family was found to be downregulated and play important roles in EMT, cell proliferation and apoptosis [34] . Other tumor suppressors include miR-26, miR-34a, and miR-192 [35] . Oncogenic miRNAs are relatively scarce. Some of the reasons include that oncogenes are preferentially analyzed in tumor studies, and miRNAs regulate gene expression mainly by degrading mRNA or suppressing translation. In this study, we measured miR-222 levels and found that they were closely related to tumor malignancy. Further study revealed that miR-222 could inhibit the expression of p27, a key cell-cycle regulator. Interestingly, we generated a series of PDAC cells with different metastatic abilities, Hs 766T (parent cells) to Hs 766T-L3 cells, which are the third-generation primary cells of a metastatic liver tumor. We found that miR-222 expression levels increased successively when p27 expression levels decreased successively. In PDAC samples, miR-222 expression levels were also inversely correlated with those of p27. Thus, the expression of miR-222, an oncogenic gene, was confirmed in PDAC. Our results were also consistent with other studies of HCC or bladder cancer [29, 36] .
Recently, more and more studies indicate that changes in gene localization could result in different or even opposite biological functions. For example, cytoplasmic and nuclear PCBP1 were reported to have different regulatory functions [37] ; KLF4, which is primarily located in the nucleus and functions as a tumor suppressor, exerts oncogenic effects when expressed in the cytoplasm [38] . We suggest that p27 also has opposite functions when its cellular distribution changes in PDAC. First, consistent with our results, p27 acts as a tumor suppressor when located in the nucleus; we found that normal or slightly malignant cells, such as HEK 293, HPDE, Capan-1 and Hs 766T cells, all express high levels of p27 in the nucleus. Second, in highly malignant cells, such as Hs 766T-L3 cells, low levels of p27 are expressed, but p27 is mainly located in the cytoplasm. Our results are in line with those of Catherine Denicourt's melanoma study [39] ; in this study, the re-localization of p27 to the cytoplasm was closely related to tumor invasion or metastasis rather than to tumor suppression, as when it was originally localized to the nucleus in melanoma. We investigated the possible mechanisms of p27 re-localization and found that activated AKT induced p27 phosphorylation, thus leading to high levels of cytoplasmic p27 expression; these results were further confirmed by WB using proteins from the nuclear and cytoplasmic protein separation assays. Furthermore, it should be noted that the total p27 expression seems to be negatively associated with tumor malignancy; possible reasons for this include that the majority of tumor cells express p27 in the nucleus, and cytoplasmic p27 levels in highly malignant cells are low. The results above may be important for the clinical application of p27 therapies in the future: if p27 is distributed mainly to the cytoplasm in some patients, p27 therapeutics may fail.
Exosomes are regarded as stable and effective carriers between different tumor cells, and different tumor-related nucleic acids or proteins in exosomes were found to play diagnostic or regulatory roles [40, 41] . Our research revealed that tumor cells can transfer miR-222 to other cells via exosomes to increase malignancy; these results are different from those of some other studies [42] . First, we screened miR-222 in tumor exosomes rather than in tumor tissue, and the experimental cell lines were highly metastatic daughter cells of the control cells. Second, we used many different experiments to confirm exosome transfer, and exosomal miR-222 transfer was confirmed and imaged. Third, we showed that exosomal miR-222 transfer between PDAC cells was functional. Finally, we analyzed plasma exosomal miR-222 expression Based on the data we described above, we proposed our hypothesis of the role of exosomal miR-222 in PDAC (Fig. 8) : Normal or slightly malignant cells expressed less miR-222 but more nuclear p27, once they received exosomes containing high levels of miR-222 that were released from malignant tumor cells, Slightly malignant cells exerted at least two biological effects: on the one hand, the total p27 expression was inhibited; on the other hand, the miR-222/PPP2R2A/AKT pathway was activated to phosphorylate p27, that leading to cytoplasmic p27 expression. These effects resulted in cell proliferation, invasion and metastasis. Furthermore, miR-222 can enter into blood circulation via exosome communication and be detected in clinical practice.
Conclusion
We screened oncogenic miR-222 from tumor exosomes via microarray analysis and revealed that miR-222 regulates p27 expression; we also found that miR-222 could phosphorylate p27 via the miR-222/PPP2R2A/AKT pathway to re-localize p27. Exosomal miR-222 transfer was also confirmed in vitro, and exosomal miR-222 expression was correlated with tumor progression and prognosis. Thus, exosomal miR-222 may play important regulatory and diagnostic roles in PDAC. 
